INTRODUCTION
Acute myeloid leukemia (AML) with mutated nucleophosmin (NPM1) and aberrant cytoplasmic expression of nucleophosmin (NPMc+ AML) 1 
MATERIALS AND METHODS

Samples from AML patients
We studied 41 leukemia samples from 38 consecutive NPM1-mutated AML patients, including 3 cases evaluated at diagnosis and relapse (Table 1 ; supplemental 24 and/or mutational analysis. 1 The study was approved by the University of Perugia ethical committees and written informed consent for analysis of leukemic samples was obtained at each participating center in accordance with the Declaration of Helsinki.
Flow cytometric immunophenotyping
Immunophenotyping was performed using the following antibodies: peridinin chlorophyll protein complex (PerCP) 
MACS cell sorting
All leukemia samples were subjected to CD34+ cell selection by MACS cell sorting technology, according to manufacturer's instruction (CD34 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany). Both positive and negative cell fractions were analyzed for CD34+ cells percentage.
FACS cell sorting
The CD34+ cells MACS-enriched cell fraction from 1 case and leukemic bulk cells from 2 additional cases were subjected to sorting for specific cell subpopulations by the cell sorter FACSAria (Becton Dickinson) equipped with blue, red, and violet lasers. Dead cells were excluded by analyzing forward scatter (FSC) vs side scatter (SSC) dot plots. Doublets were excluded by FSC-H vs FSC-A dot plots. Data compensation and analysis were obtained using the "logicle" display method.
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Detection of NPM1 mutated protein and gene NPM1 mutant protein was detected on lysates from 1-2 x 10 6 cells by WB analysis with a rabbit polyclonal antibody specific for the mutated NPM1 protein. 10, 24 Lysate from the human leukemic cell line OCI/AML3 26 was used as positive control for NPM1 mutant A protein expression. In selected cases, NPM1 mutations were analyzed by either direct sequencing 8 or genomic DNA fragments analysis.
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Immunohistochemical studies
Immunohistochemistry was performed on human and mice paraffin-embedded samples fixed in B5 (Bio-Optica, Milan, Italy) for 2 hours; bone tissues were also decalcified in EDTA (Osteodec, Bio-Optica) for 5-6 hours. Antigen retrieval was carried out by microwaving in 0.1 mM EDTA, pH 8.0.
Cytoplasmic nucleophosmin was revealed using a mouse anti-NPM monoclonal antibody (mAb). 1 Other antigens included: nucleolin (C23) (mAb MS-3, Santa Cruz
Biotechnology, Santa Cruz, CA); myeloperoxidase (rabbit anti-myeloperoxidase antibody, Dakocytomation, Glostrup, Denmark); macrophage-restricted CD68 (mouse mAb PG-M1 generated by B.F.); CD20 (mouse mAb, L26, Dakocytomation); CD3 (rabbit mAb, SP7, ThermoScientific, Fremont, CA); CD45 and glycophorin (Dakocytomation Figure 1A ). In all of them, a specific 37 kDa molecular weight band, corresponding to NPM1 mutant protein, was detected ( Figure 1A ). This signal could not be due to contaminating CD34-leukemic cells since in 12 of 13 samples CD34+ cells accounted for >90% of the total analyzed population (2 x 10 6 cells) whilst our WB detection method is not sensitive enough to reveal NPM1 mutant protein from cells that accounts for ≤ 10% ( Figure 1B ). Moreover, unlike that observed in AML cells dilution assay ( Figure 1B ), the WB signal intensity was not decreased in the CD34+ purified cells as compared to leukemic bulk ( Figure 1A ). Thus, it is conceivable that even in the case with lower CD34+ cell purity (pt. 30, 79% CD34+ cell purity) (Table 1) , positive signal could not be ascribed to contaminating CD34-cells.
In 1 leukopenic patient (pt. 19), only 0.1 x 10 6 CD34+ bone marrow cells (99.7% pure) could be recovered, that were not enough for WB analysis. In this case, NPM1 mutation A was detected by direct gene sequencing in purified CD34+, CD34-and presorting cell populations ( Figure 1C ). Again, detection of NPM1 mutation in the CD34+ cells could not be due to the minority of contaminating CD34-cells (0.3%), since the latter was under the detection threshold (about 25%) of our direct gene sequencing assay (supplemental Figure 1 ). Figure 2A .
In 2 of 5 cases ( Figure 2B ).
In the remaining 3 cases (pts. 22, 25, 26) the FACS-sorted CD34+/CD38-subpopulation (purity of 96%, 99% and 99%, respectively) was NPM1-mutated by either direct gene sequencing (pt. 22, harboring NPM1 mutation 7 3 ) or genomic DNA fragment analysis (pts. 25 and 26). The finding of NPM1 mutation in these samples could not be due to the small number of contaminating CD34-cells (range 1%-4%) since this is below the detection threshold of our molecular assays (Supplemental Figure 1) . A representative case (pt. 25) harboring the NPM1 mutation in the CD34+/CD38-and CD34+/CD38+ cell fractions (both 99% pure), as well as in the bulk leukemic population, is depicted in Figure   2C and D. In this case, the CD34+/CD38-cells also carried FLT3-ITD mutation ( Figure 2C In conclusion, our results clearly indicate that in the 5 cases studied, the CD34+/CD38-subpopulation carried the mutated NPM1 gene and protein. To address this issue, we double-stained for CD34 and NPM bone marrow paraffin sections from 5 NPM1-mutated AML containing a percentage of CD34+ cells ranging between 2 and 20%. In all cases, the CD34+ cells showed aberrant cytoplasmic positivity for nucleophosmin (NPMc+) and nucleus-restricted positivity for another nucleolar protein (C23/nucleolin) that was used as control ( Figure 3 A-D) . Double-stained CD34+/NPMc+ cells were randomly scattered in bone marrow biopsies from patients, without predilection for areas close to bone trabeculae or marrow vessels. Expression of cytoplasmic NPM1 in CD34+ cells (both CD38-and CD38+ subsets) was also found by flow cytometry (Figure 3 E, F). (Table 2; supplemental Tables 3 and 4 The leukemic nature of all hCD45+ engrafted cells was supported in 7 of 10 cases where the morphology and immunophenotype of engrafted cells paralleled that of patient's primary AML (Table 2; supplemental Table 4 ). In these cases, all engrafted cells were myeloid (hCD45+/CD33+ and myeloperoxidase-positive) (Figure 4 B, E, F). In contrast, no hCD45+ cells co-expressing CD19 and/or CD20 (suggestive of normal engraftment) were detected in the great majority of evaluated mice ( Table 2 ; supplemental Table 4 (Table 2) . AML development was usually seen later than normal human hematopoietic engraftment (Table 2) 
Patterns of engraftment of CD34-cells from NPM1-mutated AML in immunocompromised mice
Main aim of this study was to characterize the small fraction of CD34+ cells in NPM1-mutated AML. However, there is experimental evidence that, in some AML cases 37,38 (including NPM1-mutated AML 21 ), also the CD34-population may contain the LICs. Therefore, we assessed the engraftment capability of CD34-cells from 15 NPM1-mutated AMLs (Table 4 ; supplemental Table 5 ). Inoculation of these cells in immunocompromised mice led to 4 different patterns which varied also according to the injected cell dose:
Pattern 1) CD34-cells from 10 patients did not engraft in mice when inoculated at doses ≤ 1 x 10 6 (supplemental Table 5 ). In contrast, CD34+ cells from 4 of these cases generated typical NPMc+ AML, when injected in mice at the same doses (Table 2: pts. 17, 30, 32, 34;
supplemental Table 4 ). Moreover, CD34-cells from pts. 17, 32 and 34 did not outgrow into AML colonies in CFCs assays (data not shown);
Pattern 2) Engraftment of CD34-as typical NPMc+ AML (similar to that observed injecting mice with purified CD34+ cells) was observed in 2 cases (not shown). In both of them, CD34-cells were purified from NPM1-mutated AML at relapse (Table 4: pts. 8R, 23). Selfrenewal capability of CD34-cells from these cases was demonstrated after transfer to secondary recipients (Table 3) ;
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Frequency of LICs in CD34+ and CD34-cell fractions in NPM1-mutated AML
The presence and frequency of LICs in specific cell fractions was assessed by limiting-dilution transplantation assay in 3 cases (pts. 17, 22R, 34). Results are shown in size. As an example, the bone marrow sample from pt. 10 (Table 2) In pts. 17 and 22R, we were able to track CD34 expression in engrafted leukemia at different time points. Interestingly, starting from CD34+ cells with a purity of 98.3% and 99.9%, respectively, we observed a progressive reduction of the percentage of CD34+ cells within the leukemic bulk with time (e.g. pt 17, from 52% at 9 weeks to 35% at 12
weeks and 14% at 20 weeks) ( Figure 5 G-I; Table 2 ) and outgrowth of leukemia from 15.8
to 52 and 80% at correspondent time points (Table 2) .
Our findings suggest the CD34-phenotype of NPM1-mutated AML developing in mice may be due to CD34 downregulation. ; #Analyzed on Cytomics FC500 cytometer equipped with the CXP analysis software (Beckman Coulter Inc.); *after 2 purification step; **CD34+ MACS-enriched cell fraction used for FACS sorting; ***CD34+ FACS sorted; §Two distinct cell populations (CD34 low and CD34 bright ).
For personal use only. a Experiments to calculate frequency of LIC were performed with these samples (see Table 5 ); // Full details on the characteristics of the engraftment are provided in supplemental Table 4 ; b Paired experiments using correspondent doses of CD34+ versus CD34-cells were performed with these samples (see Table 5 for details of pts. 17 and 34); † † Higher cell doses of CD34-cells gave rise to engraftment as pattern 4 (see 'Results' section for description and Table 4 (E-F: APAAP; hematoxylin counterstaining). All images were collected using an Olympus
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